BACKGROUND: Dementia is a highly prevalent condition worldwide. Its chronic and progressive presentation has an impact on physical and psychosocial characteristics and on public healthcare. Our aim was to summarize evidence from Cochrane reviews on non-pharmacological treatments for cognitive disorders and dementia. DESIGN AND SETTING: Review of systematic reviews, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo. METHODS: Cochrane reviews on non-pharmacological interventions for cognitive dysfunctions and/or type of dementia were included. For this, independent assessments were made by two authors. RESULTS: Twenty-four reviews were included. These showed that carbohydrate intake and validation therapy may be beneficial for cognitive disorders. For dementia, there is a potential benefit from physical activity programs, cognitive training, psychological treatments, aromatherapy, light therapy, cognitive rehabilitation, cognitive stimulation, hyperbaric oxygen therapy in association with donepezil, functional analysis, reminiscence therapy, transcutaneous electrical stimulation, structured decision-making on feeding options, case management approaches, interventions by non-specialist healthcare workers and specialized care units. No benefits were found in relation to enteral tube feeding, acupuncture, Snoezelen stimulation, respite care, palliative care team and interventions to prevent wandering behavior. CONCLUSION: Many non-pharmacological interventions for patients with cognitive impairment and dementia have been studied and potential benefits have been shown. However, the strength of evidence derived from these studies was considered low overall, due to the methodological limitations of the primary studies.
INTRODUCTION
Dementia has been considered by the World Health Organization to be a public health priority since 2012, 1 because of its high estimated prevalence and incidence. A report published in 2016 estimated that 47.5 million people have dementia worldwide and this number is expected to almost triple by 2050, to reach 135.5 million. 2 Because of the chronic and progressive nature of this condition, the socioeconomic impact of dementia is extremely important. As a consequence of the estimated increase in prevalence, increases in the familial and societal burden and an even more significant impact on healthcare costs can be expected. 3, 4 Treatment and management of dementia are challenging because of the patients' diminished ability to adhere to therapeutics and to report adverse effects. 5 Also, dementia is not a single condition: rather, it comprises distinct diseases with different pathophysiological mechanisms. The therapeutic and preventive strategies depend particularly on understanding the etiology and other factors such as clinical features, stage of dementia and family support. Some of the most common pharmacological agents are cholinesterase inhibitors, 6 memantine, 7 memantine combined with cholinesterase inhibitors 8, 9 and antioxidants. 10, 11 There are many non-pharmacological therapies and some of them show little, if any, evidence of benefit regarding dementia.
A quick search on MEDLINE (via PubMed), using the 
OBJECTIVES
To identify and summarize Cochrane systematic reviews focusing on non-pharmacological interventions to treat cognitive impairment and dementia, regardless of etiology, and to present their findings in accordance with the quality of the evidence.
METHODS

Design
Review of Cochrane systematic reviews on interventions to treat cognitive impairment and dementia.
Setting
Discipline of Evidence-Based Medicine of Escola Paulista de
Medicina, Universidade Federal de São Paulo (UNIFESP).
Criteria for including reviews
• Types of studies
We included the latest version of completed Cochrane systematic reviews, without imposing any restriction on publication date.
Protocols relating to systematic reviews and reviews that were coded as "withdrawn" in the Cochrane Database of Systematic Reviews (CDSR) were not included.
• Types of participants
Patients diagnosed with cognitive impairment or dementia, regardless of etiology, including (but not limited to) mild cognitive impairment, vascular dementia, Alzheimer, mixed dementia and dementia secondary to other neurodegenerative diseases.
• Types of intervention Non-pharmacological interventions including (but not limited to) psychological, social and educational interventions, acupuncture, physical exercise and physical therapy.
• Types of outcomes Clinical, social and laboratory outcomes, as reported in the systematic reviews.
Search for reviews
We conducted a systematic search in the Cochrane Database of Systematic Reviews (CDSR) (via Wiley) on December 19, 2016, using a sensitive search strategy ( Table 1) .
Selection of systematic reviews
Two reviewers independently evaluated titles and abstracts of records initially retrieved on the basis of the inclusion criteria.
Disagreements were solved by reaching a consensus.
Presentation of the results
We presented the results from the systematic reviews included through a narrative structure (qualitative synthesis).
RESULTS
Search results
The initial search retrieved 183 reviews. However, only 24 fulfilled our inclusion criteria. Results from systematic reviews Among the 24 systematic reviews included, two (~8%) focused on vascular dementia, two (~8%) focused on dementia secondary to other diseases and 16 (~66.6%) focused on all types of dementia. Additionally, one study (~4%) focused on cognition as a broader topic, two (~8%) focused on both dementia and mild cognitive impairment and one (~4%) on mental disorders as a broader topic. Three reviews (12.5%) assessed caregivers' outcomes, and six (25%) focused on interventions relating to healthcare systems.
A brief summary of the systematic reviews included is presented below. The issues addressed, the main findings from each intervention and the quality of the evidence (based on the GRADE approach) are presented in Tables 2, 3 and 4. Table 2 . Continuation.
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Palliative care interventions
The review 12 (2016) had the purpose of assessing the effectiveness of palliative care interventions in cases of advanced dementia, with inclusion of two randomized controlled trials (RCTs).
Because of the heterogeneity of the data, no meta-analysis could be done. The results listed below were found:
• 
Physical exercise programs
The objective of the review 13 (2015) was to analyze physical exer- • Other secondary outcomes could not be assessed.
There was promising evidence that exercise programs might improve the ability of people with dementia to perform activities of daily living, but no evidence of benefit regarding cognition, neuropsychiatric symptoms, or depression. For further details, refer to the original abstract, available at: http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD006489.pub4/abstract.
Case management approaches to home support
Case management is an intervention for organizing and coordinating care at the level of the individual, providing long-term care for people with dementia in the community. The aim of the review Dementia/no treatment; social contact.
Benefit: caregiver strain. Adverse effects: not found.
Not assessed Table 3 . Characteristics, main findings and quality of evidence from systematic reviews focusing on caregiver-directed interventions *GRADE = Grading of Recommendations Assessment, Development and Evaluation. Tool used for assessing the quality of the body of the current evidence. High quality: low probability that further studies might change the confidence regarding the existing evidence. Moderate quality: probability that further studies will change the confidence regarding the existing evidence. Low quality: high probability that further studies will change the confidence regarding the existing evidence. Very low quality: there is much uncertainty about the information, precluding any valid interpretation.
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Intervention
Population and comparison Benefits, harms and safety Evidence quality (GRADE approach*)
Palliative care team 12 Advanced dementia hospitalized for acute illness/usual care.
No effect: modification on clinical care provided during hospital admission; mortality in hospital; decisions to forgo cardiopulmonary resuscitation
Very low
Structured aid for decision-making on feeding options 12 Advanced dementia in nursing homes/usual care.
Benefit: conflict on decisions; likelihood of discussing feeding options with a clinician.
Very low
Case management approaches 14
Dementia; home setting/ other treatments.
Benefit: number of days/month in a residential home/hospital unit; total cost of servicers; dollar expenditure (3 years); institutionalization (6 months); behavior disturbance (18 months); caregiver burden (6 months); caregiver depression; caregiver wellbeing (6 months). No effect: number of people admitted to hospital; length of time until participants were institutionalized; institutionalization (10-12 and 24 months); mortality; participants' quality of life; behavior disturbance (4, 6 and 12 months); caregivers' quality of life; caregiver burden (12 and 18 months); caregiver well-being (12 and 18 months). Table 4 . Characteristics, main findings and quality of evidence from systematic reviews focusing on healthcare system interventions *GRADE = Grading of Recommendations Assessment, Development and Evaluation. Tool used for assessing the quality of the body of the current evidence. High quality: low probability that further studies might change the confidence regarding the existing evidence. Moderate quality: probability that further studies will change the confidence regarding the existing evidence. Low quality: high probability that further studies will change the confidence regarding the existing evidence. Very low quality: there is much uncertainty about the information, precluding any valid interpretation.
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• Dollar expenditure: reduction for the total of three years (one RCT, n = 5170; MD -705.00, 95% CI -1170.31 to -239.69, P = 0.003);
• Number of days per month in a residential home or hospital unit: reduction in the case management group at six months (one RCT, n = 88; MD -5.80, 95% CI -7.93 to -3.67, P < 0.0001) and at 12 months (one RCT, n = 88; MD -7.70, 95% CI -9.38 to -6.02, P < 0.0001);
• Number of people admitted to hospital: no differences at six months (four RCTs, 439 participants), 12 months (five RCTs, 585 participants) and 18 months (five RCTs, 613 participants);
• Length of time until participants were institutionalized: uncertain effects at 12 months (one trial; hazard ratio (HR): 0.66, 95% CI 0.38 to 1.14, P = 0.14);
• Institutionalization (admission to residential or nursing homes):
significantly less likely for case management group at six months (six RCTs, n = 5741; OR 0.82, 95% CI 0.69 to 0.98, I² = 0%, P = 0.02) and at 18 months (four RCTs, n = 363; OR 0.25, 95%
CI 0.10 to 0.61, I² = 0%, P = 0.003). The effects were uncertain at 10 to 12 months (nine RCTs, n = 5990; OR 0.95, 95%
CI 0.83 to 1.08, I² = 48%, P = 0.39) and at 24 months (two RCTs, n = 201; OR 1.03, 95% CI 0.52 to 2.03, I² = 0%, P = 0.94);
• Mortality and participants' or caregivers' quality of life: no significant events (mortality: at four, six, 12, 18, 24 and 36 months; quality of life: at four, six, 12 and 18 months);
• Behavioral disorder: reduction in case management group at 18 months (2 RCTs, n = 206; SMD -0.35, 95% CI -0.63 to -0.07, I² = 0%, P = 0.01) but uncertain effects at four months (two RCTs), six months (four RCTs) and 12 months (five RCTs);
• Caregiver burden: benefits at six months (four RCTs, n = 4601; SMD -0.07, 95% CI -0.12 to -0.01, I² = 26%, P = 0.03) but uncertain effects at 12 or 18 months;
• Caregiver depression: small significant improvement in case management group at 18 months (three RCTs, n = 2,888; SMD -0.08, 95% CI -0.16 to -0.01, I² = 0%, P = 0.03);
• Caregiver wellbeing: greater improvement in the case management group at six months (one RCT, n = 65; MD -2.20 CI -4.14 to -0.26, P = 0.03) but uncertain effects at 12 or 18 months.
There was evidence that case management was beneficial for improving some outcomes relating to patients and caregivers and for lowering admissions to care homes and overall healthcare costs.
There was not enough evidence regarding whether case management might delay institutionalization in care homes, and there were uncertain results regarding patient depression, functional abilities and cognition. For further details, refer to the original abstract, available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD008345.pub2/abstract. • Clinician-rated anxiety: positive effect from psychological treatments (two trials, 65 participants; MD -4.57, 95% CI -7.81 to -1.32);
Neuropsychological rehabilitation on multiple sclerosis
• Self-rated and caregiver-rated anxiety: no difference (for selfrated: two trials, SMD 0.05, 95% CI -0.44 to 0.54; for caregiverrated: one trial, MD -2.40, 95% CI -4.96 to 0.16).
There was evidence that psychological interventions combined with usual care could reduce the symptoms of depression and clinician-rated anxiety among people with dementia. For further details, refer to the original abstract, available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009125.pub2/abstract.
Aromatherapy
The objective of the review 17 (2014) was to assess the effectiveness of aromatherapy for treating dementia. Seven RCTs (428 participants, three to 12 weeks of intervention) were included in this review, but only two were combined in a meta-analysis.
The results listed below were found (comparison: aromatherapy versus placebo):
• Agitation and behavioral symptoms: significant treatment effect from aromatherapy (one study; for agitation: n = 71, • Activities of daily living: reduction in the development of limitations (one study);
• Cognitive function, sleep, challenging behavior or psychiatric symptoms associated with dementia: no effect.
There was insufficient evidence to justify the use of brightlight therapy in cases of dementia. For further details, refer to the original abstract, available at: http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD003946.pub4/abstract.
Respite care
Respite care is any intervention designed to give rest or relief to caregivers. The review 19 (2014) aimed to assess the effect of respite care on dementia patients and their caregivers, particularly regarding institutionalization rates. Four trials (753 participants) were included, but no meta-analysis could be done. The following results were found:
• Respite care versus no respite care: no significant effects on caregiver variables (burden and psychological stress and health);
• Respite care versus polarity therapy: significant effect found in favor of polarity therapy for caregiver-perceived stress (n = 38, MD 5.80, 95% CI 1.43 to 10.17), but not for other psychological health measures and other caregiver outcomes;
• Outcomes for people with dementia: not reported in the studies. • Mood, activities of daily living, general behavioral function and behavioral problems: no effect.
There was consistent evidence that cognitive stimulation benefited cognition in cases of dementia. For further details, refer to the original abstract, available at: http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD005562.pub2/abstract.
Hyperbaric oxygen therapy for treating vascular dementia
Hyperbaric oxygen therapy (HBOT) has shown possible efficacy for treating vascular dementia. The aim of the review 23 (2012) was to assess the effectiveness and safety of HBOT in treating vascular dementia, alone or as an adjuvant treatment. One study • Other outcomes and adverse effects: not measured in this study. 
Functional analysis
Carbohydrates for cognition
Carbohydrates are essential and easily accessible macronutrients that influence cognitive performance. The aim of the review CD007220.pub2/abstract.
Special care units for behavioral problems
The purpose of special care units (SCUs) is to optimize care for dementia patients, particularly those with behavioral disorders.
The review 26 (2009) aimed to evaluate the effect of SCUs on behavioral problems, mood, need for use of restraints and use of psychotropics in treating dementia. Since no RCTs met the inclusion criteria, eight non-RCTs were selected, among which only four could be combined in a meta-analysis. The following results were found (comparison: SCUs versus traditional nursing home):
• Need for use of restraints: less need for use of restraints in SCUs after six months (two studies, OR 0.46, 95% CI 0.27 to 0.80, P = 0.006) and 12 months (one study, OR 0.49, 95% CI 0.27 to 0.88, P = 0.02);
• Mood: reduction of depressive symptoms among patients at SCUs after three months (one study, WMD -6.30 (-7.88 to -4.72) Cornell points, P < 0.00001);
• Neuropsychiatric inventory score: limited improvements for patients at SCUs (one study lasting six, 12 and 18 months);
• Use of psychotropic medication: reduced use in traditional nursing home after six months (one study, WMD 0.20, CI 0.00 to 0.40, z = 1.96, P = 0.05);
• Behavioral symptoms: no studies found.
There was no strong evidence of benefit, considering the results from non-RCTs. For further details, refer to the original abstract, available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.
CD006470.pub2/abstract.
Enteral tube feeding
Use of enteral tube feeding for patients with advanced dementia with poor nutritional intake is a frequent practice. The review 27 (2009) aimed to evaluate enteral tube nutrition for patients with advanced dementia with eating and swallowing difficulties and/ or poor nutritional intake. Seven observational controlled studies were identified. In the comparison of feeding tube versus no feeding tube, survival, nutritional status and prevalence of pressure ulcers, there was no evidence of benefit among patients receiving enteral tube feeding.
There was insufficient evidence to suggest that enteral tube feeding was beneficial among patients with advanced dementia. For further details, refer to the original abstract, available at:
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007209. pub2/abstract.
Adjunctive therapies for treating AIDS dementia complex
AIDS dementia complex is a complication from human immuno- • Neuropsychological test scores, number of patients who completed the assigned dosage of experimental medication and all-cause mortality: no significant differences between groups;
• Adverse effects: no difference between groups. 
Non-pharmacological interventions for preventing wandering
Although there seems to be a consensus in the literature that, in the majority of cases, non-pharmacological approaches for pre- • Cognition (at follow-up), mood (at follow-up) and general behavioral function (at the end of the intervention period): statistically significant benefit;
• Caregiver strain: significant decrease for caregivers participating in groups with their relative affected by dementia;
• Staff knowledge of group members' backgrounds: significantly improvement;
• Harmful effects: not identified.
In view of the limited number and low quality of studies, 
Transcutaneous electrical nerve stimulation
Transcutaneous electrical nerve stimulation (TENS), which consists of application of electrical current through electrodes to the skin, may improve cognition and behavior in cases of dementia.
The purpose of the review 32 (2003) was to determine the effect and safety of TENS for treating dementia, and also the variation in treatment parameters. Nine RCTs were selected, among which only three could be included in the meta-analysis. The following results were found (comparison: TENS versus placebo):
• Delayed eight-word recall, face recognition and motivation:
improvement in measurements (four trials) right after treatment;
• Other neuropsychological and behavioral measures: no difference between groups immediately after treatment or after six weeks.
The limited data presented in this study did not allow any definite conclusions on the possible benefits of this intervention.
For further details, refer to the original abstract, available at: http:// onlinelibrary.wiley.com/doi/10.1002/14651858.CD004032/abstract.
Validation therapy
Validation therapy is a form of therapy using specific techniques There were no other statistically significant differences between validation and social contact or between validation and usual therapy.
For further details, refer to the original abstract, available at: http:// onlinelibrary.wiley.com/doi/10.1002/14651858.CD001394/abstract. 
Snoezelen stimulation
Subjective barriers for preventing wandering
Wandering is a frequent behavioral trait among people with dementia, and it may put them at risk. The review 35 
DISCUSSION
This review of systematic reviews compiled through the Cochrane library focused on non-pharmacological interventions for treating cognitive impairment or dementia, regardless of etiology. It was not our primary objective to assess specific interventions for a given type of dementia but, rather, to present the evidence from up-to-date Cochrane reviews on dementia in general. Despite the major importance of this condition, there was almost no high-quality evidence for any of the outcomes proposed by the systematic reviews included. The primary studies presented limited methodological quality and other limitations, such as small sample sizes, lack of reporting of adverse effects and short-term measurement of outcomes. Consequently, the authors of these systematic reviews were unable to put forward any strong recommendations for clinical practice.
Three other previous reviews of systematic reviews [37] [38] [39] aimed to evaluate interventions for treating dementia. The most recent of these 37 compiled any systematic reviews that evaluated the effectiveness of non-pharmacological interventions on behavioral disturbances in cases of dementia. The authors' conclusions were similar to ours. The other review 38 focused on any kind of intervention to delay functional decline in cases of dementia. Regarding nonpharmacological interventions, the authors found only low-quality evidence relating to physical exercise and dyadic interventions.
The earliest review 39 found evidence suggesting that hand massage/gentle touch, music or music therapy and physical exercise were effective.
Differently from the others, our review only included Cochrane systematic reviews: these are developed based on rigorous explicit methods. Another important point is that we included all the outcomes proposed in the systematic reviews that were included, which was not the case for other recent reviews 37, 38 that addressed specific outcomes (behavioral disturbances and functional decline).
The limitations of the present study relate to the poor quality of the primary studies included in the systematic reviews, which lowered the strength of evidence.
Given the low quality of the primary studies, no solid recommendations for practice could be made. Some interventions seem to bring potential benefits in relation to limited outcomes, but controlled studies with high methodological quality and adequate sample sizes are needed in order to generate sound practical conclusions. The need for well-designed studies focusing on nonpharmacological interventions is particularly important, considering the personal, familial and societal burden of dementia and considering that many pharmacological interventions might not be safe in this particular population.
CONCLUSION
A wide range of non-pharmacological interventions has been studied in the context of cognitive impairment and dementia, and some have shown potential benefits. However, the strength of evidence derived from these studies was considered low overall, because of the methodological limitations of the primary studies. The 24 Cochrane systematic reviews included in this study showed that carbohydrates (glucose drink) and validation therapy may be beneficial for treating cognitive impairment. 
